Synoptic CT scan reporting of pancreatic adenocarcinoma to align with international consensus guidelines on surgical resectability: a Victorian pilot | | |
Neoadjuvant chemotherapy or upfront surgery in localized pancreatic cancer: a contemporary analysis | | 2022 |
Prognostic factors in conversion surgery following nab‐paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual‐center study | | |
Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer Using Optical Surface Management System – AlignRT as an Optical Body Surface Motion Management in Deep Breath Hold Patients: Results from a Single-Arm Retrospective Study | Cancer Management and Research | |
Precision Approaches to Pancreatic Cancer Therapy: What Now and What Next? | Current Treatment Options in Gastroenterology | |
The Future Perspectives of Redefining the Resection Margin Status in Different Cancers of Pancreas | Open Access Macedonian Journal of Medical Sciences | 2022 |
A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer | Internal Medicine | 2022 |
Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer | JAMA Network Open | 2022 |
Patterns of disease relapse and posttreatment follow‐up of patients with resected pancreatic adenocarcinoma: A single‐center analysis | Journal of Surgical Oncology | |
Proton Therapy in the Management of Pancreatic Cancer | Cancers | 2022 |
Interdisciplinary Approach of Establishing PDAC Resectability: Biochemical, Radiological and NAT Regimen Prognostic Factors—Literature Review | Medicina (Lithuania) | 2022 |
Prediction of Margin‐Negative Resection of Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy: Diagnostic Performance of NCCN Criteria for Resection vs. CT‐Determined Resectability | Journal of Hepato-Biliary-Pancreatic Sciences | |
The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer | International Journal of Clinical Oncology | |
The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways | Cancers | 2022 |
Stereotactic Ablative Radiotherapy Using CALYPSO® Extracranial Tracking for Intrafractional Tumor Motion Management—A New Potential Local Treatment for Unresectable Locally Advanced Pancreatic Cancer? Results from a Retrospective Study | Cancers | 2022 |
PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies | Cancers | 2022 |
Nationwide trends and outcomes of neoadjuvant chemotherapy in pancreatic cancer – an analysis of the Swedish national pancreatic cancer registry | Scandinavian Journal of Gastroenterology | |
Distal Pancreatectomy with En Bloc Celiac Axis Resection | | 2022 |
Pancreaticoduodenectomy with Splenic Artery Resection for Tumors of the Pancreatic Head and/or Body Invading the Splenic Artery | | 2022 |
The short-term outcomes of distal pancreatectomy with portal vein/superior mesenteric vein resection | Langenbeck's Archives of Surgery | |
Real‐world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma | ANZ Journal of Surgery | |
Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival. | Annals of Surgical Oncology | 2022 |
A multimodality review of solid and cystic pancreatic masses | | |
Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. | Annals of Surgical Oncology | 2022 |
Response: Impact of Tumor Size on Outcomes for Patients with Resectable Distal Pancreatic Cancer. | Annals of Surgical Oncology | 2022 |
Pancreatic Ductal Cell-Derived Extracellular Vesicles Are Effective Drug Carriers to Enhance Paclitaxel's Efficacy in Pancreatic Cancer Cells through Clathrin-Mediated Endocytosis. | International Journal of Molecular Sciences | 2022 |
Real-world outcomes of adjuvant gemcitabine gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma. | Therapeutic Advances in Medical Oncology | 2022 |
Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm? | Life | 2022 |
Data_Sheet_1.docx | | 2019 |
Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings. | European Journal of Radiology | 2022 |
Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: analysis using inverse probability of treatment weighting. | Journal of Hepato-Biliary-Pancreatic Sciences | 2022 |
Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis. | Cancer Medicine | 2021 |
The Association Between Neoadjuvant Therapy and Pathological Outcomes in Pancreatic Cancer Patients After Resection: Prognostic Significance of Microscopic Venous Invasion. | Annals of Surgical Oncology | 2022 |
Induction therapy with Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patients. | European Journal of Nuclear Medicine and Molecular Imaging | 2022 |
ASO Author Reflections: The Survival Advantage Persists: Benefit of Adjuvant Chemotherapy in Resected, Stage IA Pancreatic Cancer. | Annals of Surgical Oncology | 2022 |
Impact of the Cancer and Aging Research Group score and treatment intensity on survival and toxicity outcomes in older adults with advanced noncolorectal gastrointestinal cancers. | Cancer | 2022 |
Deciphering the Etiology of Weight Loss Following Pancreatectomy. | Annals of Surgical Oncology | 2022 |
Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. | Annals of Surgical Oncology | 2022 |
Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasing Perioperative Complications. | Cancers | 2022 |
Magnetic Resonance Imaging Radiomics-Based Nomogram From Primary Tumor for Pretreatment Prediction of Peripancreatic Lymph Node Metastasis in Pancreatic Ductal Adenocarcinoma: A Multicenter Study. | Journal of Magnetic Resonance Imaging | 2022 |
Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy. | Frontiers in Oncology | 2021 |
Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. | International Journal of Molecular Sciences | 2022 |
Contemporary Assessment of Need for Palliative Bypass After Aborted Pancreatoduodenectomy Following Neoadjuvant Therapy. | Journal of Gastrointestinal Surgery | 2022 |
MR-guided adaptive stereotactic body radiotherapy (SBRT) of primary tumor for pain control in metastatic pancreatic ductal adenocarcinoma (mPDAC): an open randomized, multicentric, parallel group clinical trial (MASPAC). | Radiation Oncology | 2022 |
A novel event-free survival endpoint in locally advanced pancreatic cancer | Therapeutic Advances in Medical Oncology | 2021 |
A novel method for predicting perineural invasion of distal cholangiocarcinoma on multidetector-row computed tomography | Surgery Today | 2021 |
An Evaluation of Total Internal Motions of Locally Advanced Pancreatic Cancer during SABR Using Calypso Extracranial Tracking, and Its Possible Clinical Impact on Motion Management. | Current Oncology | 2021 |
Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma | Cancer Medicine | 2021 |
Stereotactic Radiotherapy for Pancreatic Cancer: A Single-Institution Experience | Cureus | 2020 |
Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy | Abdominal Imaging | 2006 |
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancer | CPT: Pharmacometrics and Systems Pharmacology | 2021 |
Role of the microbiome in systemic therapy for pancreatic ductal adenocarcinoma (Review) | International Journal of Oncology | 2021 |
Identification of intratumoral fluid-containing area by magnetic resonance imaging to predict prognosis in patients with pancreatic ductal adenocarcinoma after curative resection | European Radiology | 2021 |
Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial | Cancer Management and Research | 2020 |
Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer | Annals of Surgical Oncology | 2021 |
Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis | Annals of Surgical Oncology | 2021 |
Minimally invasive pancreatectomy for pancreatic cancer | Suizo | 2021 |
ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer | Annals of Surgical Oncology | 2021 |
Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy | Annals of Surgical Oncology | 2021 |
Validity of using cancer registry data for comparative effectiveness research | | |
Use of Biosurgicals in Hepatobiliary Surgery | | |
Clinical Staging of Pancreatic Cancer with MDCT and MRI | | 2019 |
Role of 18F-Fluorodeoxyglucose Positron-Emission Tomography (FDG-PET) in the Management of Pancreatic Cancer | | 2019 |
Importance of Carbohydrate Antigen 19-9 Monitoring in the Management of Pancreatic Cancer | | 2019 |
Hybrid Imaging for Malignant Conditions of the Gastrointestinal Tract | | 2019 |
The Future of Multidisciplinary Care in Pancreatic Cancer | | 2019 |
Clinicopathological characteristics and therapeutic strategies of borderline resectable pancreatic carcinoma | Suizo | 2018 |
Neoadjuvant Chemoradiation for Operable Pancreatic Cancer: The Importance of Local Disease Control | | 2018 |
Cytotoxic Therapy in Advanced Pancreatic Cancer: Where We Are and Where We Are Headed | | 2018 |
Distal Pancreatectomy with En Bloc Celiac Axis Resection (DP-CAR) for Advanced Pancreatic Body Cancer | | 2017 |
Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer | | 2017 |
Pancreatic Resection After Neoadjuvant Treatment | | 2017 |
Pancreatoduodenectomy with Concomitant Vascular Resection for Pancreas Cancer | | 2017 |
Neoadjuvant Therapy for Pancreatic Cancer: a Review of the Evidence | Japanese Journal of Gastroenterological Surgery | 2017 |
Mesenteric Approach for Pancreaticoduodenectomy | | 2017 |
Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer | | 2017 |
Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer | | 2017 |
Borderline Resectable Pancreatic Cancer | | 2017 |
Comparisons between clinical guidelines for pancreatic cancer issued from ESMO, ASCO and NCCN and those from the JPS: A brief review of clinical problems of pancreatic cancer | Suizo | 2017 |
The resectable pancreatic ductal adenocarcinoma: To FNA or not to FNA? A diagnostic dilemma, FNA pros | Endoscopic Ultrasound | 2017 |
Diagnostic Applications of Nuclear Medicine: Pancreatic Cancer | | 2016 |
Erlotinib for advanced pancreatic cancer | The Cochrane Library | |
Other Indications | | 2015 |
Intraoperative and Laparoscopic Ultrasound During Pancreatic Surgery | | 2014 |
Pyrimidine Antimetabolites☆ | | 2014 |
The current status of FOLFIRINOX for unresectable pancreatic cancer | Suizo | 2014 |
Development of multidisciplinary therapy including surgical resection and chemotherapy for pancreatic cancer through clinical trials | Suizo | 2013 |
A Resected Case of Pancreatic Head Cancer Induced Duodenal Penetration and Bleeding During Neoadjuvant Chemoradiation | Japanese Journal of Gastroenterological Surgery | 2013 |
A Case of Actinomycosis in a Patient Treated with Chemotherapy Due to Recurrent Pancreatic Cancer | Korean Journal of Medicine | 2013 |
Efficacy of postoperative adjuvant chemotherapy for pancreatic cancer and surgical outcome of borderline resectable pancreatic cancer with suspected arterial involvement | Suizo | 2013 |
Positron emission tomography and computed tomography with [Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer | European Journal of Nuclear Medicine and Molecular Imaging | 2021 |
Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom? | JAMA Oncology | 2021 |
Neoadjuvant therapy contributes to nodal downstaging of pancreatic cancer | Langenbeck's Archives of Surgery | 2021 |
Adjuvant chemoradiotherapy for resected pancreas cancer | World Journal of Gastrointestinal Surgery | 2010 |
The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition | Endoscopic Ultrasound | 2017 |
Medical training fails to prepare providers to care for patients with chronic hepatitis B infection | World Journal of Gastroenterology | 2015 |
Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer | Cancers | 2020 |
MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2 | PLoS ONE | 2015 |
An increased total resected lymph node count benefits survival following pancreas invasive intraductal papillary mucinous neoplasms resection: an analysis using the surveillance, epidemiology, and end result registry database | PLoS ONE | 2014 |
Neoadjuvant treatment strategies for resectable pancreas cancer: A propensity-matched analysis of the National Cancer Database | Radiotherapy and Oncology | 2020 |